ZVRA — Zevra Therapeutics Share News
0.000.00%
Last trade - 00:00- $613.43m
- $391.86m
- $106.47m
Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales
Zevra Therapeutics Inc expected to post earnings of 11 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tenet, SLB, Digital Realty
U.S. STOCKS ON THE MOVE-Booz Allen Hamilton, Sensient, Amkor
U.S. STOCKS ON THE MOVE-Tenet Healthcare, Intel, Verizon
Zevra tanks after EU panel's negative opinion on rare disease drug
Brief: Zevra Therapeutics Provides Update On Regulatory Submission For Arimoclomol
U.S. RESEARCH ROUNDUP- Apple, Lennar, Toll Brothers
Rare disease drugmaker Zevra Therapeutics Q1 revenue jumps 78%
Ligand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 million (updated)
Brief: Zevra Therapeutics Sells Sdx Portfolio To Commave Therapeutics For $50 Million
Zevra Therapeutics beats FY 2025 revenue expectations
Brief: Zevra Therapeutics Appoints Justin Renz As Chief Financial Officer
Brief: Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (NPC)
Brief: Zevra Therapeutics Appoints Alicia Secor To Board Of Directors Announces Retirement Of Wendy Dixon
Brief: Zevra Therapeutics, Inc. Announces CFO Transition
Zevra Therapeutics misses Q3 revenue estimates
Zevra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Zevra Therapeutics Q2 revenue beats estimates